Clinical Overview
Reboxetine is a selective norepinephrine reuptake inhibitor indicated for depression in some international markets but not approved in the United States. It represents one of the few antidepressants with highly selective norepinephrine reuptake inhibition, potentially offering benefits for patients with depression characterized by fatigue, low energy, and motivation problems.
Primary Clinical Applications
Reboxetine is indicated for major depressive disorder in countries where it is available. It may be particularly useful for patients with depression accompanied by fatigue, psychomotor retardation, or lack of motivation, as norepinephrine enhancement can provide activating and energizing effects.
Mechanism and Clinical Benefits
Reboxetine selectively inhibits the norepinephrine transporter with minimal effects on serotonin, dopamine, or other neurotransmitter systems. This selective noradrenergic activity may provide antidepressant effects while potentially improving energy, motivation, and concentration without the sexual side effects commonly associated with serotonergic antidepressants.
Clinical Considerations
Reboxetine generally has fewer sexual side effects compared to SSRIs and may actually improve sexual function in some patients. However, it can cause significant cardiovascular effects including increased heart rate and blood pressure, requiring monitoring. The medication may also cause urinary retention and sleep disturbances due to its noradrenergic activity.
Prescribing Information
Dosing & Administration
Depression – Adults:
- Initial: 4 mg twice daily (8 mg daily)
- Range: 8-12 mg daily in divided doses
- Maximum: 12 mg daily
Elderly:
- Initial: 2 mg twice daily (4 mg daily)
- Range: 4-6 mg daily in divided doses
- Maximum: 6 mg daily
Administration:
- Divide daily dose into twice daily dosing
- Take with or without food
- Consistent timing each day
- Monitor blood pressure and heart rate
Indications
- Treatment of major depressive disorder (in countries where available)
- Not approved in the United States
Contraindications
- Hypersensitivity to reboxetine
- Concurrent use with MAOIs
- Severe renal impairment
- Urinary retention
- Narrow-angle glaucoma
Warnings & Precautions
- Cardiovascular effects: Monitor blood pressure and heart rate regularly
- Urinary retention: Risk in patients with prostatic hypertrophy
- Angle-closure glaucoma: May precipitate acute attack
- Suicidal ideation: Monitor for mood changes, especially early in treatment
- Withdrawal: Taper gradually when discontinuing
- Insomnia: May cause sleep disturbances
Drug Interactions
- MAOIs: Contraindicated – risk of hypertensive crisis
- CYP3A4 inhibitors: May increase reboxetine levels
- Antihypertensives: May reduce antihypertensive effectiveness
- Ergot alkaloids: Risk of hypertensive reactions
Adverse Reactions
Common (>10%):
- Dry mouth, constipation, insomnia, sweating
- Dizziness, nausea, urinary hesitancy
Cardiovascular:
- Increased heart rate, hypertension, palpitations
Advantages:
- Lower rates of sexual dysfunction compared to SSRIs
- May improve energy and motivation
- Minimal weight gain
Special Populations
- Cardiovascular Disease: Use caution, monitor blood pressure and heart rate
- Renal Impairment: Contraindicated in severe impairment
- Elderly: Start with lower doses, monitor cardiovascular effects
- Pregnancy: Limited data, use only if benefits outweigh risks
- Availability: Not available in United States
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
